Le Lézard
Classified in: Health, Science and technology, Business
Subject: JVN

Ovensa Collaborates with Takeda to Deliver an Antibody to the Brain


AURORA, ON, March 21, 2019 /CNW Telbec/ - Ovensa Inc. ("Ovensa") is pleased to announce that it has entered into a collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") to evaluate Ovensa's proprietary nanomedicine platform called TRIOZANtm for the delivery of an antibody to the brain and evaluate its performance in a CNS disease model.

"We are extremely proud of this new partnership, which demonstrates a great deal of confidence in our unique delivery system which helps therapeutic molecules better cross the human body's various barriers such as the skin, the mucous membranes or the blood-brain barrier and reach their target. Takeda is the largest pharmaceutical company in Japan and is present in more than 70 countries. We are starting this collaboration with enthusiasm and hope that this partnership will accelerate the discussions we have with some 30 other companies, "says Ovensa's President and CEO, Mr. Stéphane Gagné.

Ovensa offers a platform allowing for the development of custom nanomedicines based on trimethylchitosan - a biopolymer derived from crustacean chitosan. Whether it is for reducing the side effects of chemotherapy, changing the expression of a gene that does not function normally or eliciting an optimal immune response of an antibody in the brain, the platform allows high engineering flexibility where nanomedicines are specifically designed to cross barriers and optimize tissue or cell targeting based on the disease.

Although Ovensa's platform research focuses on complex diseases for which there are few available treatments such as brain cancer and Alzheimer's Disease, it also applies to other therapeutic areas such as metabolic diseases, animal health or antibiotic resistance. Also using its patented TRIOZANtm platform, Ovensa is conducting trials with its collaborators to develop new custom nanomedicines using cannabinoids such as cannabidiol (CBD) to treat various diseases including certain cancers, diseases of the central nervous system and pain.

Terms of the agreement with Takeda have not been disclosed.

About Ovensa

Ovensa is a preclinical stage company fighting inherent therapeutic resistance in complex diseases by generating advanced nanotherapeutics using its proprietary TRIOZANtm Delivery Platform. The company focuses on advancing its lead candidate in glioblastoma as well as generating novel nanotherapeutic candidates in collaboration with pharmaceutical companies for applications in CNS and immuno-oncology.

 

SOURCE Ovensa


These press releases may also interest you

at 04:45
87% of shoppers search for products online. ECommerceCompanies.com, a B2B marketplace connecting brands with eCommerce designers and developers, identified the best eCommerce marketing companies that help brands boost their online visibility and...

at 04:30
FinVolution Group ("FinVolution", or the "Company") , a leading fintech platform in China, today announced that it will report its first quarter 2020 unaudited financial results, on wednesday, May 27, 2020, before the open of U.S. markets....

at 04:23
Enzymatica and its partner STADA have extended its agreement for the cold spray ViruProtect® (ColdZyme) to cover another 19 countries in Europe. With the extended agreement STADA has provided order estimates of about SEK 20 million for 2020. The...

at 03:38
Guide Infrared ("the Company"), a leading Chinese manufacturer of infrared thermal imaging systems based in China Optical Valley, has released its first-quarter earnings snapshot. In the first quarter, Guide Infrared is expected to book a profit of...

at 03:30
Rokmaster Resources Corp. ("Rokmaster" or the "Company") is pleased to announce that it has closed the first tranche of the non-brokered financing (the "Financing") involving the issuance of flow-through units (the "Flow-Through Units") and...

at 03:10
Champignon Brands Inc. ("Champignon" or the "Company") , a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to augment its board of directors through the appointment of accomplished business...



News published on 21 march 2019 at 07:00 and distributed by: